Literature DB >> 16831275

[Effect of silencing of hyaluronidase gene HYAL1 by RNA interference on proliferation of human breast cancer cells].

Jin-Xiang Tan1, Guo-Sheng Ren, Gang Tu, Xiao-Tao Li, Xiao-Yi Wang, Liang Ran.   

Abstract

BACKGROUND &
OBJECTIVE: It is reported that hyaluronidase is related to malignant potentiality of human breast cancer. This study was to investigate whether HYAL1 RNA interference (RNAi) could effectively inhibit gene mRNA expression as well as cell proliferation in human breast cancer cells.
METHODS: Chemically synthesized double stranded RNA (dsRNA) targeting HYAL1 was transfected into human breast cancer cell lines MDA-MB-231, MDA-MB-453S, ZR-75 and ZR-75-30 using SiPORT lipid. The transfection efficiency was observed under a fluorescence confocal microscopy. Expression of HYAL1 mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR). Cell proliferation and cell cycle were determined by MTT and flow cytometry assay, respectively.
RESULTS: HYAL1 siRNA effectively inhibited HYAL1 mRNA expression (P<0.05), cell proliferation (P<0.05), and induced cell cycle arrest in G0/G1 phase with a significant decrease of cells in S-phase(P<0.05).
CONCLUSION: HYAL1-siRNA may be used as a new approach in human breast cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831275

Source DB:  PubMed          Journal:  Ai Zheng


  2 in total

1.  Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.

Authors:  Toshiaki Watanabe; Takashi Kobunai; Yoko Yamamoto; Keiji Matsuda; Soichiro Ishihara; Keijiro Nozawa; Hisae Iinuma; Tsuyoshi Konishi; Hisanaga Horie; Hiroki Ikeuchi; Kiyoshi Eshima; Tetsuichiro Muto
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

2.  Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis.

Authors:  Jin-Xiang Tan; Xiao-Yi Wang; Xin-Liang Su; Hong-Yuan Li; Yuan Shi; Liang Wang; Guo-Sheng Ren
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.